Stock Events

ObsEva SA. 

$0
72
-$0-99% Friday 16:35

Statistics

Day High
0
Day Low
0
52W High
0.4
52W Low
0
Volume
228
Avg. Volume
97,951
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OBSEF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap177.47B
Amgen Inc. competes in the biopharmaceutical sector focusing on treatments in areas that may overlap with ObsEva's reproductive health products.
Merck &
MRK
Mkt Cap323.59B
Merck & Co., Inc. offers a broad range of health solutions including women's health, directly competing with ObsEva's portfolio.
Pfizer
PFE
Mkt Cap163.88B
Pfizer Inc. has a diverse range of pharmaceutical products, including those in women's health, making it a competitor.
Novo Nordisk
NVO
Mkt Cap481.67B
Novo Nordisk A/S focuses on hormone replacement therapies and other treatments that can compete with ObsEva's reproductive health products.
Bristol-Myers Squibb
BMY
Mkt Cap82.02B
Bristol-Myers Squibb Company operates in various therapeutic areas, including those that could compete with ObsEva's focus areas.
Abbvie
ABBV
Mkt Cap300.69B
AbbVie Inc. has a strong presence in women's health through its hormonal therapies, competing with ObsEva.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.57B
Teva Pharmaceutical Industries Limited offers generic and specialty medicines, including in women's health, posing competition to ObsEva.
Lilly(Eli) &
LLY
Mkt Cap901.36B
Eli Lilly and Company has a portfolio that includes treatments for conditions in women's health, competing with ObsEva.
GSK
GSK
Mkt Cap81.16B
GlaxoSmithKline plc engages in the creation of pharmaceuticals, including those for women's health, making it a competitor.
Sanofi
SNY
Mkt Cap130B
Sanofi offers a broad range of healthcare solutions, including in areas that compete with ObsEva's focus on reproductive health.

About

ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women's reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
Show more...
CEO
Dr. Ernest Loumaye M.D., OB/GYN, Ph.D.
Employees
15
Country
CH
ISIN
CH1260041939
WKN
000A3EELW

Listings